What have we learned about TP53-mutated acute myeloid leukemia? by Moazzam Shahzad, Muhammad Kashif Amin, Naval G. Daver, Mithun Vinod Shah, Devendra Hiwase, Daniel A. Arber, Mohamed A. Kharfan-Dabaja, Talha Badar

Get full text

Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia by Gabriel N. Mannis, Camille N. Abboud, Naval G. Daver, Guru Subramanian Guru Murthy, Eunice S. Wang, Terrence J. Bradley, George Yaghmour, Pankit Vachhani, Suresh Kumar Balasubramanian, Chong Chyn Chua, Chun Yew Fong, Adam S. Asch, Mei Dong, Shuang Li, Taravat Bagheri, Parul Doshi, Paresh Vyas, Monzr M. Al Malki

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text